Construction and characterization of the HMGB1 mutant as a competitive antagonist to HMGB1 induced cytokines release

Biochemical and Biophysical Research Communications

Volumn 372, Issue 4, 2008, Pages 703-707

  Yuan, Zhiqiang ^a   Chen, Jing ^a   Zhang, Yan ^a   Peng, Yizhi ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antagonist; Cytokine; HMGB1; Inflammation; Monocyte; Mutant

Indexed keywords

COMPLEMENTARY DNA; CYTOKINE; GLYCINE; HIGH MOBILITY GROUP B1 PROTEIN;

ARTICLE; BINDING AFFINITY; CELL CULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; MOLECULAR CLONING; MONOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; REAL TIME POLYMERASE CHAIN REACTION;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTI-INFLAMMATORY AGENTS; CELL LINE; HMGB1 PROTEIN; HUMANS; MONOCYTES; MUTATION; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 46149126132     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.05.115     Document Type: Article

References (22)

1. Bustin M. Revised nomenclature for high mobility group (HMG) chromosomal proteins. Trends Biochem. Sci. 26 (2001) 152-153
2. Goodwin G.H., Sanders C., and Johns E.W. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur. J. Biochem. 38 (1973) 14-19
3. Li J., Kokkola R., Tabibzadeh S., Yang R., Ochani M., Qiang X., Harris H.E., Czura C.J., Wang H., Ulloa L., Wang H., Warren H.S., Moldawer L.L., Fink M.P., Andersson U., Tracey K.J., and Yang H. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol. Med. 9 (2003) 37-45
4. Skoko D., Wong B., Johnson R.C., and Marko J.F. Micromechanical analysis of the binding of DNA-bending proteins HMGB1, NHP6A, and HU reveals their ability to form highly stable DNA-protein complexes. Biochemistry 43 (2004) 13867-13874
5. Pallier C., Scaffidi P., Chopineau-Proust S., Agresti A., Nordmann P., Bianchi M.E., and Marechal V. Association of chromatin proteins high mobility group box (HMGB) 1 and HMGB2 with mitotic chromosomes. Mol. Biol. Cell 14 (2003) 3414-3426
6. Yuan F., Gu L., Guo S., Wang C., and Li G.M. Evidence for involvement of HMGB1 protein in human DNA mismatch repair. J. Biol. Chem. 279 (2004) 20935-20940
7. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., Frazier A., Yang H., Ivanova S., Borovikova L., Manogue K.R., Faist E., Abraham E., Andersson J., Andersson U., Molina P.E., Abumrad N.N., Sama A., and Tracey K.J. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285 (1999) 248-251
8. Wang H., Yang H., and Tracey K.J. Extracellular role of HMGB1 in inflammation and sepsis. J. Intern. Med. 255 (2004) 320-331
9. Scaffidi P., Misteli T., and Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418 (2002) 191-195
10. Wang H., Li W., Goldstein R., Tracey K.J., and Sama A.E. HMGB1 as a potential therapeutic target. Novartis. Found. Symp. 280 (2007) 73-85
11. Karlsson S., Pettila V., Tenhunen J., Laru-Sompa R., Hynninen M., and Ruokonen E. HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis. Intensive Care Med. (2008)
12. Klune J.R., Billiar T.R., and Tsung A. HMGB1 preconditioning: therapeutic application for a danger signal. J. Leukoc. Biol. 83 (2008) 558-563
13. Unoshima M. Therapeutic effect of anti-HMGB1 antibody and anti-RAGE antibody on SIRS/sepsis. Nippon Rinsho 62 (2004) 2323-2329
14. Parrish W., and Ulloa L. High-mobility group box-1 isoforms as potential therapeutic targets in sepsis. Methods Mol. Biol. 361 (2007) 145-162
15. Eriksson M. Should high mobility group box-1 protein (HMGB1) be measured in patients with severe sepsis and septic shock? If so, when, where, and how?. Crit. Care Med. 33 (2005) 682-683
16. Yang H., Ochani M., Li J., Qiang X., Tanovic M., Harris H.E., Susarla S.M., Ulloa L., Wang H., DiRaimo R., Czura C.J., Wang H., Roth J., Warren H.S., Fink M.P., Fenton M.J., Andersson U., and Tracey K.J. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. USA 101 (2004) 296-301
17. Ulloa L., Ochani M., Yang H., Tanovic M., Halperin D., Yang R., Czura C.J., Fink M.P., and Tracey K.J. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc. Natl. Acad. Sci. USA 99 (2002) 12351-12356
18. Guo R.F., and Ward P.A. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23 (2005) 821-852
19. Mantell L.L., Parrish W.R., and Ulloa L. Hmgb-1 as a therapeutic target for infectious and inflammatory disorders. Shock 25 (2006) 4-11
20. Ulloa L., and Messmer D. High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev. 17 (2006) 189-201
21. Agresti A., and Bianchi M.E. HMGB proteins and gene expression. Curr. Opin. Genet. Dev. 13 (2003) 170-178
22. Li J., Wang H., Mason J.M., Levine J., Yu M., Ulloa L., Czura C.J., Tracey K.J., and Yang H. Recombinant HMGB1 with cytokine-stimulating activity. J. Immunol. Methods 289 (2004) 211-223